You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthyl biscoumacetate
Accession NumberDB08794
TypeSmall Molecule
GroupsWithdrawn
DescriptionEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Structure
Thumb
Synonyms
Ethyl bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetate
Ethyldicoumarol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PelentanNot Available
TromexanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII08KL644731
CAS number548-00-5
WeightAverage: 408.362
Monoisotopic: 408.084517475
Chemical FormulaC22H16O8
InChI KeyJCLHQFUTFHUXNN-UHFFFAOYSA-N
InChI
InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
IUPAC Name
ethyl 2,2-bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
SMILES
CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCoumarins and derivatives
Sub ClassHydroxycoumarins
Direct Parent4-hydroxycoumarins
Alternative Parents
Substituents
  • 4-hydroxycoumarin
  • Benzopyran
  • 1-benzopyran
  • Pyranone
  • Pyran
  • Benzenoid
  • Heteroaromatic compound
  • Vinylogous acid
  • Carboxylic acid ester
  • Lactone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Oxacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.937
Blood Brain Barrier+0.5382
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6415
P-glycoprotein inhibitor INon-inhibitor0.7527
P-glycoprotein inhibitor IINon-inhibitor0.7433
Renal organic cation transporterNon-inhibitor0.8741
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.9049
CYP450 3A4 substrateNon-substrate0.6717
CYP450 1A2 substrateNon-inhibitor0.6524
CYP450 2C9 inhibitorInhibitor0.8453
CYP450 2D6 inhibitorNon-inhibitor0.9562
CYP450 2C19 inhibitorInhibitor0.6966
CYP450 3A4 inhibitorNon-inhibitor0.9273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6137
Ames testNon AMES toxic0.6498
CarcinogenicityNon-carcinogens0.9167
BiodegradationNot ready biodegradable0.7564
Rat acute toxicity2.7178 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.938
hERG inhibition (predictor II)Non-inhibitor0.896
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point153-154Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).
water solubility153 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0677 mg/mLALOGPS
logP2.18ALOGPS
logP1.67ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.82ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.95 m3·mol-1ChemAxon
Polarizability39.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).

General ReferencesNot Available
External Links
ATC CodesB01AA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Ethyl biscoumacetate.
AceclofenacAceclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.
AcetaminophenAcetaminophen may increase the anticoagulant activities of Ethyl biscoumacetate.
AcetohexamideAcetohexamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
AdapaleneAdapalene may increase the anticoagulant activities of Ethyl biscoumacetate.
AllopurinolAllopurinol may increase the anticoagulant activities of Ethyl biscoumacetate.
AllylestrenolThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Allylestrenol.
AlprostadilAlprostadil may increase the anticoagulant activities of Ethyl biscoumacetate.
AlteplaseAlteplase may increase the anticoagulant activities of Ethyl biscoumacetate.
AltrenogestThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Ethyl biscoumacetate.
AmdinocillinAmdinocillin may increase the anticoagulant activities of Ethyl biscoumacetate.
AmineptineAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
AmiodaroneAmiodarone may increase the anticoagulant activities of Ethyl biscoumacetate.
AmitriptylineAmitriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
AmobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Amobarbital.
AmoxapineAmoxapine may increase the anticoagulant activities of Ethyl biscoumacetate.
AmoxicillinAmoxicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
AmpicillinAmpicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
AnagrelideAnagrelide may increase the anticoagulant activities of Ethyl biscoumacetate.
AncrodAncrod may increase the anticoagulant activities of Ethyl biscoumacetate.
AnistreplaseAnistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.
AntipyrineAntipyrine may increase the anticoagulant activities of Ethyl biscoumacetate.
Antithrombin III humanEthyl biscoumacetate may increase the anticoagulant activities of Antithrombin III human.
ApixabanApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.
ApremilastApremilast may increase the anticoagulant activities of Ethyl biscoumacetate.
AprotininThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Aprotinin.
ArdeparinArdeparin may increase the anticoagulant activities of Ethyl biscoumacetate.
ArgatrobanArgatroban may increase the anticoagulant activities of Ethyl biscoumacetate.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ethyl biscoumacetate.
AtorvastatinAtorvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
AzapropazoneAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.
AzathioprineAzathioprine may decrease the anticoagulant activities of Ethyl biscoumacetate.
AzelastineAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.
AzlocillinAzlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.
BalsalazideBalsalazide may increase the anticoagulant activities of Ethyl biscoumacetate.
BarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.
BatroxobinBatroxobin may increase the anticoagulant activities of Ethyl biscoumacetate.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Ethyl biscoumacetate.
BecaplerminBecaplermin may increase the anticoagulant activities of Ethyl biscoumacetate.
BemiparinBemiparin may increase the anticoagulant activities of Ethyl biscoumacetate.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Benzathine benzylpenicillinBenzathine benzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
Benzylpenicillin PotassiumBenzylpenicillin Potassium may increase the anticoagulant activities of Ethyl biscoumacetate.
BeraprostBeraprost may increase the anticoagulant activities of Ethyl biscoumacetate.
BezafibrateBezafibrate may increase the anticoagulant activities of Ethyl biscoumacetate.
BicalutamideThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Bicalutamide.
BivalirudinBivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.
BosentanThe metabolism of Ethyl biscoumacetate can be increased when combined with Bosentan.
BromfenacBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.
CangrelorCangrelor may increase the anticoagulant activities of Ethyl biscoumacetate.
CapecitabineThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Capecitabine.
CarbamazepineThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Carbamazepine.
CarbenicillinCarbenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
CarbimazoleCarbimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.
CarprofenCarprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
CastanospermineCastanospermine may increase the anticoagulant activities of Ethyl biscoumacetate.
CefacetrileCefacetrile may increase the anticoagulant activities of Ethyl biscoumacetate.
CefaclorCefaclor may increase the anticoagulant activities of Ethyl biscoumacetate.
CefadroxilCefadroxil may increase the anticoagulant activities of Ethyl biscoumacetate.
CefalotinCefalotin may increase the anticoagulant activities of Ethyl biscoumacetate.
CefamandoleCefamandole may increase the anticoagulant activities of Ethyl biscoumacetate.
CefapirinCefapirin may increase the anticoagulant activities of Ethyl biscoumacetate.
CefazolinCefazolin may increase the anticoagulant activities of Ethyl biscoumacetate.
CefiximeCefixime may increase the anticoagulant activities of Ethyl biscoumacetate.
CefmenoximeCefmenoxime may increase the anticoagulant activities of Ethyl biscoumacetate.
CefmetazoleCefmetazole may increase the anticoagulant activities of Ethyl biscoumacetate.
CefonicidCefonicid may increase the anticoagulant activities of Ethyl biscoumacetate.
CefoperazoneCefoperazone may increase the anticoagulant activities of Ethyl biscoumacetate.
CefotaximeCefotaxime may increase the anticoagulant activities of Ethyl biscoumacetate.
CefotetanCefotetan may increase the anticoagulant activities of Ethyl biscoumacetate.
CefotiamCefotiam may increase the anticoagulant activities of Ethyl biscoumacetate.
CefoxitinCefoxitin may increase the anticoagulant activities of Ethyl biscoumacetate.
CefradineCefradine may increase the anticoagulant activities of Ethyl biscoumacetate.
CeftazidimeCeftazidime may increase the anticoagulant activities of Ethyl biscoumacetate.
CeftizoximeCeftizoxime may increase the anticoagulant activities of Ethyl biscoumacetate.
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Ethyl biscoumacetate.
CefuroximeCefuroxime may increase the anticoagulant activities of Ethyl biscoumacetate.
CelecoxibCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
CephalexinCephalexin may increase the anticoagulant activities of Ethyl biscoumacetate.
CephaloglycinCephaloglycin may increase the anticoagulant activities of Ethyl biscoumacetate.
CephaloridineCephaloridine may increase the anticoagulant activities of Ethyl biscoumacetate.
CerivastatinCerivastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
CertoparinEthyl biscoumacetate may increase the anticoagulant activities of Certoparin.
Chloral hydrateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Chloral hydrate.
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Ethyl biscoumacetate.
ChloroquineChloroquine may increase the anticoagulant activities of Ethyl biscoumacetate.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ethyl biscoumacetate.
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.
CholestyramineCholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilostazolCilostazol may increase the anticoagulant activities of Ethyl biscoumacetate.
CimetidineCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.
CiprofibrateCiprofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.
CitalopramCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
Citric AcidCitric Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
ClofibrateClofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.
ClomipramineClomipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
ClonixinClonixin may increase the anticoagulant activities of Ethyl biscoumacetate.
ClopidogrelClopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.
CloxacillinCloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.
Coenzyme Q10Coenzyme Q10 may increase the anticoagulant activities of Ethyl biscoumacetate.
ColesevelamColesevelam can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Collagenase.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Ethyl biscoumacetate.
CranberryCranberry may increase the anticoagulant activities of Ethyl biscoumacetate.
CyclacillinCyclacillin may increase the anticoagulant activities of Ethyl biscoumacetate.
CyclobenzaprineCyclobenzaprine may increase the anticoagulant activities of Ethyl biscoumacetate.
D-LimoneneD-Limonene may increase the anticoagulant activities of Ethyl biscoumacetate.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.
DalteparinDalteparin may increase the anticoagulant activities of Ethyl biscoumacetate.
DanaparoidDanaparoid may increase the anticoagulant activities of Ethyl biscoumacetate.
DapoxetineDapoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
DasatinibDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.
DeferasiroxThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Ethyl biscoumacetate.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deoxycholic Acid.
DesipramineDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
DesirudinEthyl biscoumacetate may increase the anticoagulant activities of Desirudin.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ethyl biscoumacetate.
DesogestrelThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Desogestrel.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.
DexmethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dexmethylphenidate.
DextranEthyl biscoumacetate may increase the anticoagulant activities of Dextran.
Dextran 40Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 40.
Dextran 70Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 70.
Dextran 75Ethyl biscoumacetate may increase the anticoagulant activities of Dextran 75.
DiclofenacDiclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Ethyl biscoumacetate.
DicoumarolDicoumarol may increase the anticoagulant activities of Ethyl biscoumacetate.
DienestrolDienestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.
DienogestThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.
DiflunisalDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.
DihydrotestosteroneDihydrotestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.
DipyridamoleDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.
DisulfiramThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Disulfiram.
DitazoleDitazole may increase the anticoagulant activities of Ethyl biscoumacetate.
DosulepinDosulepin may increase the anticoagulant activities of Ethyl biscoumacetate.
DoxepinDoxepin may increase the anticoagulant activities of Ethyl biscoumacetate.
DronedaroneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ethyl biscoumacetate.
DroxicamDroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
DydrogesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Dydrogesterone.
EconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Econazole.
Edetic AcidEdetic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
EdoxabanEdoxaban may increase the anticoagulant activities of Ethyl biscoumacetate.
EfavirenzThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.
EnoxaparinEnoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate.
EpinastineEpinastine may increase the anticoagulant activities of Ethyl biscoumacetate.
EpirizoleEpirizole may increase the anticoagulant activities of Ethyl biscoumacetate.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ethyl biscoumacetate.
EpoprostenolThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.
ErythromycinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Erythromycin.
EscitalopramEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
EsmirtazapineEsmirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.
EsomeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Esomeprazole.
EstradiolEstradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.
EstriolEstriol may decrease the anticoagulant activities of Ethyl biscoumacetate.
EstroneEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.
Etacrynic acidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.
EtanerceptEtanercept may increase the anticoagulant activities of Ethyl biscoumacetate.
EthanolThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Ethanol.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.
EthotoinEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacEtodolac may increase the anticoagulant activities of Ethyl biscoumacetate.
EtofenamateEtofenamate may increase the anticoagulant activities of Ethyl biscoumacetate.
EtofibrateEtofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.
EtonogestrelThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoposideEtoposide may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ethyl biscoumacetate.
ExenatideExenatide may increase the anticoagulant activities of Ethyl biscoumacetate.
exisulindexisulind may increase the anticoagulant activities of Ethyl biscoumacetate.
FenbufenFenbufen may increase the anticoagulant activities of Ethyl biscoumacetate.
FenfluramineFenfluramine may increase the anticoagulant activities of Ethyl biscoumacetate.
FenofibrateFenofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.
FenoprofenFenoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ethyl biscoumacetate.
FloctafenineFloctafenine may increase the anticoagulant activities of Ethyl biscoumacetate.
FlucloxacillinFlucloxacillin may increase the anticoagulant activities of Ethyl biscoumacetate.
FluconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluconazole.
FlunixinFlunixin may increase the anticoagulant activities of Ethyl biscoumacetate.
FluorouracilThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluorouracil.
FluoxetineFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
FluoxymesteroneFluoxymesterone may increase the anticoagulant activities of Ethyl biscoumacetate.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
FluvastatinFluvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
FluvoxamineFluvoxamine may increase the anticoagulant activities of Ethyl biscoumacetate.
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Ethyl biscoumacetate.
FosphenytoinFosphenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.
Fusidic AcidThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fusidic Acid.
GefitinibGefitinib may increase the anticoagulant activities of Ethyl biscoumacetate.
GemfibrozilGemfibrozil may increase the anticoagulant activities of Ethyl biscoumacetate.
GenisteinGenistein may decrease the anticoagulant activities of Ethyl biscoumacetate.
GestodeneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Gestodene.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Ethyl biscoumacetate.
GlibornurideGlibornuride may increase the anticoagulant activities of Ethyl biscoumacetate.
GliclazideGliclazide may increase the anticoagulant activities of Ethyl biscoumacetate.
GlimepirideGlimepiride may increase the anticoagulant activities of Ethyl biscoumacetate.
GlipizideGlipizide may increase the anticoagulant activities of Ethyl biscoumacetate.
GliquidoneGliquidone may increase the anticoagulant activities of Ethyl biscoumacetate.
GlisoxepideGlisoxepide may increase the anticoagulant activities of Ethyl biscoumacetate.
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.
GlutethimideThe metabolism of Ethyl biscoumacetate can be increased when combined with Glutethimide.
GlyburideGlyburide may increase the anticoagulant activities of Ethyl biscoumacetate.
GriseofulvinThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Griseofulvin.
HeminHemin may increase the anticoagulant activities of Ethyl biscoumacetate.
HeparinHeparin may increase the anticoagulant activities of Ethyl biscoumacetate.
HexestrolHexestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.
HexobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Hexobarbital.
HirulogHirulog may increase the anticoagulant activities of Ethyl biscoumacetate.
HMPL-004HMPL-004 may increase the anticoagulant activities of Ethyl biscoumacetate.
Hydroxyprogesterone caproateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ethyl biscoumacetate.
IbudilastIbudilast may increase the anticoagulant activities of Ethyl biscoumacetate.
IbuprofenIbuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
IbuproxamIbuproxam may increase the anticoagulant activities of Ethyl biscoumacetate.
IcatibantIcatibant may increase the anticoagulant activities of Ethyl biscoumacetate.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ethyl biscoumacetate.
IfenprodilIfenprodil may increase the anticoagulant activities of Ethyl biscoumacetate.
IfosfamideIfosfamide may increase the anticoagulant activities of Ethyl biscoumacetate.
IloprostIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.
IloprostThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Iloprost.
ImipramineImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
IndalpineIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.
IndomethacinIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.
IndoprofenIndoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
IsoxicamIsoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
ItraconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Itraconazole.
IvermectinIvermectin may increase the anticoagulant activities of Ethyl biscoumacetate.
KebuzoneKebuzone may increase the anticoagulant activities of Ethyl biscoumacetate.
KetoconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
KetorolacKetorolac may increase the anticoagulant activities of Ethyl biscoumacetate.
L-CarnitineL-Carnitine may increase the anticoagulant activities of Ethyl biscoumacetate.
LansoprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Lansoprazole.
LeflunomideLeflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.
LepirudinLepirudin may increase the anticoagulant activities of Ethyl biscoumacetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ethyl biscoumacetate.
LevonorgestrelThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Levonorgestrel.
LevothyroxineLevothyroxine may increase the anticoagulant activities of Ethyl biscoumacetate.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ethyl biscoumacetate.
LiothyronineLiothyronine may increase the anticoagulant activities of Ethyl biscoumacetate.
LiotrixLiotrix may increase the anticoagulant activities of Ethyl biscoumacetate.
LixisenatideLixisenatide can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
LornoxicamLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
LovastatinLovastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Lu AA21004Lu AA21004 may increase the anticoagulant activities of Ethyl biscoumacetate.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.
MasoprocolMasoprocol may increase the anticoagulant activities of Ethyl biscoumacetate.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
MedrogestoneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Megestrol acetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
MercaptopurineMercaptopurine may decrease the anticoagulant activities of Ethyl biscoumacetate.
MesalazineMesalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
MestranolMestranol may decrease the anticoagulant activities of Ethyl biscoumacetate.
MetamizoleMetamizole may increase the anticoagulant activities of Ethyl biscoumacetate.
MethimazoleMethimazole may decrease the anticoagulant activities of Ethyl biscoumacetate.
MethohexitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methohexital.
MethylphenidateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate.
MethylphenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Methylphenobarbital.
MethyltestosteroneMethyltestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.
MeticillinMeticillin may increase the anticoagulant activities of Ethyl biscoumacetate.
MetronidazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Metronidazole.
MevastatinMevastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
MezlocillinMezlocillin may increase the anticoagulant activities of Ethyl biscoumacetate.
MiconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ethyl biscoumacetate.
MilrinoneMilrinone may increase the anticoagulant activities of Ethyl biscoumacetate.
MirtazapineMirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
NabumetoneNabumetone may increase the anticoagulant activities of Ethyl biscoumacetate.
NadroparinEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.
NafcillinNafcillin may increase the anticoagulant activities of Ethyl biscoumacetate.
NaftifineNaftifine may increase the anticoagulant activities of Ethyl biscoumacetate.
NaproxenNaproxen may increase the anticoagulant activities of Ethyl biscoumacetate.
NCX 4016NCX 4016 may increase the anticoagulant activities of Ethyl biscoumacetate.
NeomycinNeomycin may increase the anticoagulant activities of Ethyl biscoumacetate.
NepafenacNepafenac may increase the anticoagulant activities of Ethyl biscoumacetate.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
NimesulideNimesulide may increase the anticoagulant activities of Ethyl biscoumacetate.
NintedanibThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Nintedanib.
NorethisteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Norethisterone.
NortriptylineNortriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
ObinutuzumabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.
OlanzapineOlanzapine may increase the anticoagulant activities of Ethyl biscoumacetate.
OlopatadineOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.
OlsalazineOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ethyl biscoumacetate.
OmeprazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.
OrgoteinOrgotein may increase the anticoagulant activities of Ethyl biscoumacetate.
OritavancinThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Oritavancin.
OtamixabanOtamixaban may increase the anticoagulant activities of Ethyl biscoumacetate.
OxacillinOxacillin may increase the anticoagulant activities of Ethyl biscoumacetate.
OxandroloneOxandrolone may increase the anticoagulant activities of Ethyl biscoumacetate.
OxaprozinOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.
OxymetholoneOxymetholone may increase the anticoagulant activities of Ethyl biscoumacetate.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.
ParecoxibParecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
ParnaparinParnaparin may increase the anticoagulant activities of Ethyl biscoumacetate.
ParoxetineParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
PentobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Pentobarbital.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ethyl biscoumacetate.
PhenindionePhenindione may increase the anticoagulant activities of Ethyl biscoumacetate.
PhenobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Phenobarbital.
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Ethyl biscoumacetate.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.
PhenytoinPhenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Ethyl biscoumacetate.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.
PiperacillinPiperacillin may increase the anticoagulant activities of Ethyl biscoumacetate.
PirfenidonePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.
PiroxicamPiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
PitavastatinPitavastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
PivampicillinPivampicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
PivmecillinamPivmecillinam may increase the anticoagulant activities of Ethyl biscoumacetate.
PlasminPlasmin may increase the anticoagulant activities of Ethyl biscoumacetate.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ethyl biscoumacetate.
PosaconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Ethyl biscoumacetate.
PravastatinPravastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
PrimidoneThe metabolism of Ethyl biscoumacetate can be increased when combined with Primidone.
Procaine benzylpenicillinProcaine benzylpenicillin may increase the anticoagulant activities of Ethyl biscoumacetate.
ProgesteroneThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.
PropacetamolPropacetamol may increase the anticoagulant activities of Ethyl biscoumacetate.
PropafenoneThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Ethyl biscoumacetate.
Protein CEthyl biscoumacetate may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeEthyl biscoumacetate may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
PTC299PTC299 may increase the anticoagulant activities of Ethyl biscoumacetate.
QuinestrolQuinestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.
QuinidineQuinidine may increase the anticoagulant activities of Ethyl biscoumacetate.
QuinineQuinine may increase the anticoagulant activities of Ethyl biscoumacetate.
ResveratrolResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.
ReteplaseReteplase may increase the anticoagulant activities of Ethyl biscoumacetate.
ReviparinEthyl biscoumacetate may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.
RivaroxabanEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Ethyl biscoumacetate.
RosuvastatinRosuvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
SalicylamideSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
SalsalateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.
SCH-530348SCH-530348 may increase the anticoagulant activities of Ethyl biscoumacetate.
SecobarbitalThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.
SelexipagSelexipag may increase the anticoagulant activities of Ethyl biscoumacetate.
SeratrodastSeratrodast may increase the anticoagulant activities of Ethyl biscoumacetate.
SertralineSertraline may increase the anticoagulant activities of Ethyl biscoumacetate.
SevofluraneSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.
SimvastatinSimvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.
SRT501SRT501 may increase the anticoagulant activities of Ethyl biscoumacetate.
St. John's WortThe metabolism of Ethyl biscoumacetate can be increased when combined with St. John's Wort.
StanozololStanozolol may increase the anticoagulant activities of Ethyl biscoumacetate.
StreptokinaseStreptokinase may increase the anticoagulant activities of Ethyl biscoumacetate.
SucralfateSucralfate may decrease the anticoagulant activities of Ethyl biscoumacetate.
SugammadexSugammadex may increase the anticoagulant activities of Ethyl biscoumacetate.
SulbactamSulbactam may increase the anticoagulant activities of Ethyl biscoumacetate.
SulfadiazineSulfadiazine may increase the anticoagulant activities of Ethyl biscoumacetate.
SulfamethoxazoleSulfamethoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
SulfinpyrazoneThe metabolism of Ethyl biscoumacetate can be decreased when combined with Sulfinpyrazone.
SulfisoxazoleSulfisoxazole may increase the anticoagulant activities of Ethyl biscoumacetate.
SulindacSulindac may increase the anticoagulant activities of Ethyl biscoumacetate.
SulodexideSulodexide may increase the anticoagulant activities of Ethyl biscoumacetate.
SuprofenSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ethyl biscoumacetate.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ethyl biscoumacetate.
TamoxifenThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tamoxifen.
TegafurThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Tegafur.
TenecteplaseTenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.
TenoxicamTenoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
TepoxalinTepoxalin may increase the anticoagulant activities of Ethyl biscoumacetate.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.
TesmilifeneTesmilifene may increase the anticoagulant activities of Ethyl biscoumacetate.
TestosteroneTestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.
ThiamylalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiopental.
Thyroid, porcineThyroid, porcine may increase the anticoagulant activities of Ethyl biscoumacetate.
TianeptineTianeptine may increase the anticoagulant activities of Ethyl biscoumacetate.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
TiboloneTibolone may increase the anticoagulant activities of Ethyl biscoumacetate.
TicagrelorTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.
TicarcillinTicarcillin may increase the anticoagulant activities of Ethyl biscoumacetate.
TiclopidineTiclopidine may increase the anticoagulant activities of Ethyl biscoumacetate.
TinzaparinTinzaparin may increase the anticoagulant activities of Ethyl biscoumacetate.
TipranavirTipranavir may increase the anticoagulant activities of Ethyl biscoumacetate.
TirofibanTirofiban may increase the anticoagulant activities of Ethyl biscoumacetate.
TolazamideTolazamide may increase the anticoagulant activities of Ethyl biscoumacetate.
TolbutamideTolbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.
TolmetinTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.
ToremifeneToremifene may increase the anticoagulant activities of Ethyl biscoumacetate.
TositumomabThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Tositumomab.
TramadolTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.
TranilastTranilast may increase the anticoagulant activities of Ethyl biscoumacetate.
TrapidilTrapidil may increase the anticoagulant activities of Ethyl biscoumacetate.
TrazodoneTrazodone may increase the anticoagulant activities of Ethyl biscoumacetate.
TreprostinilTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.
TreprostinilThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Treprostinil.
TriflusalTriflusal may increase the anticoagulant activities of Ethyl biscoumacetate.
TrimipramineTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Ethyl biscoumacetate.
UrokinaseUrokinase may increase the anticoagulant activities of Ethyl biscoumacetate.
ValdecoxibValdecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethyl biscoumacetate.
VilazodoneVilazodone may increase the anticoagulant activities of Ethyl biscoumacetate.
Vitamin EVitamin E may increase the anticoagulant activities of Ethyl biscoumacetate.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ethyl biscoumacetate.
VoriconazoleThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the anticoagulant activities of Ethyl biscoumacetate.
VortioxetineVortioxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
WarfarinWarfarin may increase the anticoagulant activities of Ethyl biscoumacetate.
XimelagatranXimelagatran may increase the anticoagulant activities of Ethyl biscoumacetate.
ZafirlukastThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Zafirlukast.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
ZeranolZeranol may decrease the anticoagulant activities of Ethyl biscoumacetate.
ZileutonZileuton may increase the anticoagulant activities of Ethyl biscoumacetate.
ZimelidineZimelidine may increase the anticoagulant activities of Ethyl biscoumacetate.
ZomepiracZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Manganese ion binding
Specific Function:
This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). Essential for proliferation of fetal skin fibroblasts.
Gene Name:
GLUL
Uniprot ID:
P15104
Molecular Weight:
42064.15 Da
References
  1. Sharaev PN, Bogdanov NG, Sarycheva IK, Zhukova EE: [Allosteric regulation of glucosamine synthetase activity by naphthoquinone derivatives and ethyl ester of di-(4-oxycumarinyl-3)-acetic acid]. Biokhimiia. 1981 Feb;46(2):342-6. [PubMed:7195738 ]
Comments
comments powered by Disqus
Drug created on October 08, 2010 15:27 / Updated on August 17, 2016 12:24